[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-fibrogen":3},{"head":4,"company":37,"invest":42,"children":43,"shops":44,"category":45,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":5,"brandHonor":5,"brandTel":12,"establishdate":13,"brandBirth":14,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":15,"status":16,"isDeleted":16,"comment":5,"remark":5,"logoExistStatus":17,"imageExistStatus":17,"industryId":5,"industryRanking":5,"score":5,"enterName":18,"mallShopList":19,"brandSummary":5,"likes":5,"unlikes":5,"follow":5,"pagetitle":20,"pagekeywords":21,"pagedesc":22,"brandContent":23,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":32,"businessscope":33,"ownBrand":5,"enterTelphone":12,"enterWebsite":34,"business":35,"enterQq":5,"enterMail":36,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"90370","\u002Fprofile\u002Fupload\u002F2023\u002F12\u002F02\u002Fa8ff900cce29fc780696ff79fa1056c3.gif","FibroGen珐博进","fibrogen",88979,10006,"010-58141999","1993年","美国",398,0,"1","珐博进（中国）医药技术开发有限公司",[],"FibroGen珐博进简介-珐博进西药-品牌之家","FibroGen珐博进品牌介绍,珐博进西药好不好,珐博进怎么样,珐博进,珐博进(中国)医药技术开发有限公司","FibroGen珐博进品牌简介，品牌之家为你介绍珐博进(中国)医药技术开发有限公司旗下FibroGen珐博进品牌信息，包括品牌介绍、联系方式、主营产品、最新评论、点赞数量等，告诉你珐博进西药怎么样，致力于帮助你了解FibroGen珐博进真实有效的品牌相关信息。","FibroGen是一家位于美国旧金山的生物医药公司，于1993年成立，一直专注于医学领域内的前沿技术的研究和开发，并在低氧诱导因子（HIF）、脯氨酰羟化酶抑制（PHI）和结缔组织生长因子（CTGF）等方面取得了突破性的成就。\n\n珐博进（中国）医药技术开发有限公司（简称“珐博进（中国）”）是一家于2011年在北京经济技术开发区成立的生物医药科技公司，致力于开发新作用机制的创新药和医疗器械，以满足中国患者尚未满足的临床需求。母公司美国珐博进总部位于美国旧金山市，是一家在纳斯达克上市的公司。至2019年年底，珐博进（中国）投资总额超10亿元，员工200多人。珐博进（中国）在上海市和沧州市设有分公司，上海分公司主要开展临床研究和医学事务活动，沧州分公司于2018年10月建成生产罗沙司他原料药的工厂，为北京的罗沙司他制剂工厂供应原料药。\n\n珐博进（中国）及其母公司一直坚持原始创新，致力于研发一系列具有独特新作用机制的新药，将其在低氧诱导因子（HIF）和结缔组织生长因子（CTGF）生物学和临床开发方面的首创性科研成果投入应用领域，以促进治疗贫血、纤维化疾病和癌症的创新药物开发。珐博进（中国）还在研发一种以高纯度重组III型人胶原制成的透明生物合成角膜，拟作为创新型III类医疗器械注册。\n\n在北京市坚持和强化全国科技创新中心定位和建设具有全球影响力的科技创新中心的规划指引下，珐博进（中国）充分利用母公司充裕的资金和优势技术的支持，在中国本地研发造福中国广大患者、使中国领先世界的几款新药，在北京开展创新药研发和产业化工作已经取得成效。\n\n以核心产品罗沙司他的研发作为起点，珐博进（中国）希望成长为一家中国领先、世界一流的生物制药企业，立足北京，服务全国，为北京市强化全国科技创新中心定位和建设具有全球影响力的科技创新中心贡献力量。","北京市北京经济技术开发区科创六街88号院7号楼2单元101-601室","91110302585804919L","有限责任公司(台港澳法人独资)","文思意","2011-11-28","北京市工商行政管理局北京经济技术开发区分局","2011-11-28 至 2031-11-27","2025-01-09","250,952.76万(元)","药品和医疗器械技术的开发、转让、咨询；货物进出口、技术进出口（涉及配额许可证管理和专项管理规定管理的商品按照国家有关规定办理）；销售自产产品；生产药用中间体和原料药（限外地分公司经营）；生产硬胶囊剂。（市场主体依法自主选择经营项目，开展经营活动；依法须经批准的项目，经相关部门批准后依批准的内容开展经营活动；不得从事国家和本市产业政策禁止和限制类项目的经营活动。）","www.fibrogen.cn","科技推广和应用服务业","pressrelease@fibrogen.cn",{"enterId":38,"enterName":18,"province":5,"city":5,"area":5,"detailaddress":24,"unifiedscc":25,"enterType":26,"enterLegalperson":27,"enterStablishdate":28,"regauthority":29,"licenseValidity":30,"approvaldate":31,"regcapital":32,"incapital":32,"businessscope":33,"ownBrand":5,"enterTelphone":12,"enterWebsite":34,"business":35,"performance":39,"socialSecurity":40,"registrationNumber":41,"enterQq":5,"enterMail":36,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":16,"regtrademark":5,"remark":5},"88979","开业","127人","110000450190871",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[46],{"createTime":47,"updateTime":48,"createBy":5,"updateBy":5,"industryId":49,"webId":5,"industryName":50,"industryAlias":5,"industryIcon":5,"industryTrans":51,"pageTitle":52,"pageDesc":53,"pageKeywords":54,"mainTitle":55,"pageSubtitle":56,"indSummary":57,"industryLevel":58,"parentId":59,"parentName":5,"sortOrder":60,"status":16,"classifyVisit":5,"totalVisits":61,"searchName":5,"starLevel":5,"limit":5},"2000-01-01 00:00:00","2026-06-16 16:50:00","10006","生物科技","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F19f46e89d8cd077b73c7adb33bb2b59f.png","生物科技公司十大排行榜-国内知名生物科技公司有哪些-ZGALL品牌榜","2026年十大生物科技公司排行榜最新发布，生物科技公司十大排行榜前十名有中国生物、中国生物制药、百济神州、恒瑞、豪森药业、百利天恒、康方、复星医药、石药、信达。生物科技十大品牌排行榜由品牌研究部门收集整理大数据分析研究得出，帮助你了解中国生物科技公司有哪些。","生物科技公司排名前十有哪些,中国生物科技公司排名前十,生物科技有限公司排名,中国生物科技公司排名,全国生物科技公司排名","生物科技品牌排行榜","2026生物科技公司，生物制药公司排行榜，国内生物医药科技公司有哪些","生物科技哪个好？品牌TOP榜权威发布2026年生物科技名录；居前十的有：中国生物CNBG、中国生物制药、百济神州BeiGene、恒瑞医药、豪森药业、百利天恒、康方Akesobio、复星医药、石药CSPC、信达生物Innovent等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",3,1411,99,589]